Insite Vision Inc (INSV) 0.3465 $INSV InSite Vision

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Insite Vision Inc (INSV) 0.3465 $INSV

InSite Vision Terminates QLT Deal in Favor of Sun Pharma
Zacks Equity Research - Zacks Investment Research - Wed Sep 16, 3:50PM CDT
InSite Vision Inc. (INSV) announced that it has terminated its agreement with QLT Inc. (QLTI).
QLTI: 3.02 (-0.04), GILD: 100.65 (-0.16), REGN: 503.92 (+12.71)

InSite Vision enters into merger agreement with Sun Pharma at USD0.35 per share
M2 - Wed Sep 16, 5:41AM CDT
Ophthalmologic company InSite Vision (OtherOTC:INSV) revealed on Tuesday the launch of a merger agreement with a subsidiary of Sun Pharmaceutical Industries through a tender offer.

QLT Announces Termination of Merger Agreement With InSite Vision
GlobeNewswire - Tue Sep 15, 5:16PM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" today announced that its agreement to acquire InSite Vision Incorporated (OTCBB:INSV) ("InSite" has been terminated.
QLTI: 3.02 (-0.04), QLT.TO: 3.94 (-0.06)

InSite Vision and Sun Pharma Enter into Merger Agreement
Business Wire - Tue Sep 15, 3:23PM CDT
--InSite Terminates Merger Agreement with QLT Inc.
QLTI: 3.02 (-0.04)

Eye Infections Global Clinical Trials Review, H2, 2015
M2 - Thu Sep 10, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/376x9w/eye_infections) has announced the addition of the "Eye Infections Global Clinical Trials Review, H2, 2015" report to their offering. This clinical trial report provides an overview of Eye Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Eye Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Reasons to Buy - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned - Ajanta Pharma - Alcon - Allergan - Dompe Farmaceutici - InSite Vision - Laboratoires Thea - Merck & Co. - Novartis - SIFI - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/37...infections
AGN: 274.84 (-1.32), MRK: 50.95 (-0.07), VRX.TO: 227.56 (+4.67), NVS: 91.90 (-0.71)

Is Another Amendment of QLT-InSite Vision Deal Coming Up?
Zacks Equity Research - Zacks Investment Research - Tue Sep 08, 3:25PM CDT
InSite Vision Inc. (INSV), which is set to be acquired by QLT Inc. (QLTI), announced that it has received a superior unsolicited offer from a global pharmaceutical company.
QLTI: 3.02 (-0.04), GILD: 100.65 (-0.16), REGN: 503.92 (+12.71)

QLT Provides Additional Update on Its Proposed Acquisition of InSite Vision Incorporated
GlobeNewswire - Fri Sep 04, 8:01PM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company" announces that it has been advised by InSite Vision Incorporated ("InSite" that the board of directors of InSite has determined, in good faith and after consultation with its independent financial and legal advisors, that the second unsolicited offer, as announced in QLT's press release on September 3, 2015, from the multi-national pharmaceutical company (the "Bidder" to acquire all of the issued and outstanding shares of InSite (the "New Proposal" constitutes a "Company Superior Proposal", as defined in the Amended and Restated Agreement and Plan of Merger, dated June 8, 2015, by and among Insite, QLT and Isotope Acquisition Corp., as amended and restated on July 16, 2015 and August 26, 2015 (the "Amended and Restated Merger Agreement" .
QLTI: 3.02 (-0.04), QLT.TO: 3.94 (-0.06)

InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire InSite for $0.35 per Share in Cash Constitutes a "Company Superior Proposal"
Business Wire - Fri Sep 04, 4:49PM CDT
InSite Vision Inc. (OTCBB:INSV) today announced that InSite's Board of Directors has determined that the previously announced unsolicited offer from a global pharmaceutical company (the "Bidder" to acquire all outstanding shares of InSite Vision common stock at $0.35 per share in an all-cash transaction constitutes a "Company Superior Proposal" as defined in InSite's previously announced definitive agreement with QLT Inc. dated as of August 26, 2015 (NASDAQ:QLTI) (TSX:QLT).
QLTI: 3.02 (-0.04), QLT.TO: 3.94 (-0.06)

QLT Provides Further Update on Its Proposed Acquisition of InSite Vision Incorporated
GlobeNewswire - Thu Sep 03, 5:35PM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company" announces that it has been advised by InSite Vision Incorporated ("InSite" that InSite has received a second unsolicited offer from the multi-national pharmaceutical company which initially made an unsolicited offer, as announced in QLT's press release on August 10, 2015, to acquire all of the issued and outstanding shares of InSite (the "New Proposal" . The New Proposal is only subject to due diligence regarding the recently filed BromSite patent lawsuit. InSite has further advised QLT that the board of directors of InSite, in consultation with its financial and legal advisors, will carefully review all aspects of the New Proposal, and has not changed its recommendation with respect to the proposed merger with QLT pursuant to the Amended and Restated Agreement and Plan of Merger, dated June 8, 2015, by and among InSite, QLT and Isotope Acquisition Corp., as amended and restated on July 16, 2015 and August 26, 2015 (the "Amended and Restated Merger Agreement" . The Amended and Restated Merger Agreement continues in full force and effect.
QLTI: 3.02 (-0.04), QLT.TO: 3.94 (-0.06)

InSite Vision Receives Second Unsolicited Acquisition Proposal for $0.35 per Share From a Global Pharmaceutical Company
Business Wire - Thu Sep 03, 3:12PM CDT
InSite Vision Inc. (OTCBB:INSV) today announced that the Company has received a second unsolicited proposal from a global pharmaceutical company to acquire all outstanding shares of InSite Vision common stock at an increased price of $0.35 per share in cash. The proposal is only subject to due diligence regarding the recently filed BromSite(TM) patent lawsuit. InSite Vision believes the lawsuit is without merit.
QLTI: 3.02 (-0.04)

InSite Vision Announces New Date for Special Stockholder Meeting
Business Wire - Wed Sep 02, 5:25PM CDT
InSite Vision Incorporated (OTCBB:INSV), a company developing ophthalmic products for unmet eye care needs, today announced that the company's Special Meeting of Stockholders to vote on certain matters in connection with the transaction with QLT Inc., including a proposal to adopt a Second Amended and Restated Agreement and Plan of Merger, will now be held at 10:00 a.m. Pacific Time on October 9, 2015, for stockholders of record on September 8, 2015. InSite Vision had previously announced that the Special Meeting would be held on September 30, 2015. The Special Meeting will be held at InSite Vision's headquarters at 965 Atlantic Avenue, Alameda, California. InSite Vision plans to mail the definitive proxy statement for the Special Meeting in early September 2015.
QLTI: 3.02 (-0.04)

InSite Vision Named in BromSite Patent Lawsuit; Company Believes Lawsuit Is Without Merit
Business Wire - Wed Sep 02, 3:05PM CDT
InSite Vision Inc. (OTCBB: INSV) today announced that Johnson Matthey Pharmaceutical Materials, Inc. (Johnson Matthey) has filed a patent lawsuit in the United States District Court for the District of Delaware in connection with activities relating to InSite Vision's New Drug Application (NDA) seeking commercial approval from the U.S. Food and Drug Administration (FDA) for BromSite(TM) (0.075% bromfenac) for the treatment of inflammation and prevention of pain associated with cataract surgery.

QLT Provides Update on Its Proposed Acquisition of InSite Vision Incorporated
GlobeNewswire - Fri Aug 21, 7:39AM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company" announces that it has been advised by InSite Vision Incorporated ("InSite" that the board of directors of InSite has determined in good faith after consultation with its independent financial and legal advisors that the previously announced unsolicited offer from a multi-national pharmaceutical company (the "Bidder" to acquire all of the issued and outstanding shares of InSite (the "Proposal" constitutes a "Company Superior Proposal" as defined in the Agreement and Plan of Merger, dated June 8, 2015, by and among Insite, QLT and Isotope Acquisition Corp., as amended and restated (the "Merger Agreement" . InSite has further advised QLT that InSite intends, subject to QLT's right to match the Proposal, to terminate the Merger Agreement and enter into an agreement with the Bidder to implement the Proposal.
QLTI: 3.02 (-0.04), QLT.TO: 3.94 (-0.06)

InSite Vision Determines that an Unsolicited Offer from a Multi-National Pharmaceutical Company to Acquire InSite for $0.25 in Cash Constitutes a "Company Superior Proposal"
Business Wire - Fri Aug 21, 7:30AM CDT
InSite Vision Inc. (OTCBB:INSV) today announced that InSite's Board of Directors determined that the previously announced unsolicited offer from a multi-national pharmaceutical company (the "Bidder" to acquire InSite for $0.25 per share in an all-cash transaction constitutes a "Company Superior Proposal" as defined in InSite's previously announced definitive agreement with QLT Inc. dated as of June 8, 2015, as amended (NASDAQ: QLTI) (TSX: QLT). Under the terms of the QLT merger agreement, QLT would acquire InSite in an all-stock transaction in which shareholders of InSite will receive 0.048 QLT shares for each InSite share they hold.
QLTI: 3.02 (-0.04), QLT.TO: 3.94 (-0.06)

Blepharitis Pipeline Review, H2 2015 - Reviews Key Players Involved in the Therapeutics Development for Blepharitis
M2 - Wed Aug 19, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cb3rdq/blepharitis) has announced the addition of the "Blepharitis - Pipeline Review, H2 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Blepharitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Blepharitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Blepharitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Blepharitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned - Allergan Plc - Foamix Pharmaceuticals Ltd. - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - NicOx S.A. For more information visit http://www.researchandmarkets.com/research/cb...lepharitis
AGN: 274.84 (-1.32), FOMX: 6.84 (+0.17)

InSite Vision Announces FDA Acceptance of NDA Filing for BromSite(TM) (0.075% bromfenac)
Business Wire - Mon Aug 17, 3:05PM CDT
--Marketing approval is being sought for use in treatment of inflammation and prevention of pain after cataract surgery

InSite Vision falls to net loss of USD6.6m for Q2 2015
M2 - Wed Aug 12, 5:29AM CDT
Ophthalmic company InSite Vision (Other OTC:INSV) stated on Tuesday that it recorded a net loss of USD6.6m (USD0.05 per share) for the quarter ended 30 June 2015.

InSite Vision Announces Date for Special Stockholder Meeting
Business Wire - Tue Aug 11, 6:58PM CDT
InSite Vision Incorporated (OTCBB:INSV), a company developing ophthalmic products for unmet eye care needs, today announced that the company's Special Meeting of Stockholders to vote on certain matters in connection with the transaction with QLT Inc., including a proposal to adopt an Agreement and Plan of Merger, will be held at 10:00 a.m. Pacific Time on September 30, 2015, for stockholders of record on August 25, 2015. The Special Meeting will be held at InSite Vision's headquarters at 965 Atlantic Avenue, Alameda, California. InSite Vision plans to mail the definitive proxy statement for the Special Meeting in early September 2015.
QLTI: 3.02 (-0.04)

InSite Reports Second Quarter 2015 Financial Results
Business Wire - Tue Aug 11, 3:05PM CDT
InSite Vision Incorporated (OTCBB: INSV) today reported financial results for the quarter ended June 30, 2015. Revenues for the quarter ended June 30, 2015 were $0.4 million compared to $6.3 million for the same period in 2014; revenues in 2014 included a $6.0 million payment from Akorn, Inc. for an amendment to their AzaSite(R) license agreement (Akorn License). Net loss for the quarter ended June 30, 2015 was $6.6 million, or $0.05 per share, compared to net income of $37.1 million, or $0.28 per share, in the second quarter of 2014. In the second quarter of 2014, InSite recorded a gain of $36.0 million on the extinguishment of the AzaSite Notes. As of June 30, 2015, cash and cash equivalents totaled $1.8 million.
QLTI: 3.02 (-0.04), AKRX: 29.90 (+0.39)

QLT Provides Update on Merger With InSite Vision Incorporated
GlobeNewswire - Mon Aug 10, 7:39AM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company" announces that it has been advised by InSite Vision Incorporated ("InSite Vision" that InSite Vision has received an unsolicited offer from a multi-national pharmaceutical company to acquire all of the issued and outstanding shares of InSite Vision (the "Proposal" . InSite Vision has further advised QLT that the board of directors of InSite Vision is reviewing the Proposal, and has not changed its recommendation with respect to the proposed merger with QLT pursuant to the Agreement and Plan of Merger (the "Merger Agreement" among QLT, InSite Vision, and Isotope Acquisition Corp., dated June 8, 2015. The Merger Agreement continues in full force and effect.
QLTI: 3.02 (-0.04), QLT.TO: 3.94 (-0.06)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 81

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 195

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 34

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 216

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 8

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 13

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 81

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 25

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 15

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 138

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading

Top 5 Most Recently Viewed Articles

Key Insights on Paragon 28, Inc. Class Action Lawsuit

Updated Category News Views 106

Understanding the Paragon 28 Class Action Lawsuit Recently, investors in Paragon 28, Inc. have been alerted about a significant class action lawsuit involving the company's financial disclosures. The litigation revolves around potential inaccuracies in previously issued financial statements. Investors must be aware that the upcoming deadline to file a lead plaintiff...

Continue Reading
Newtopia Partners with Payvider for Enhanced Health Benefits

Updated Category News Views 278

Newtopia Partners with Payvider for Enhanced Health Benefits Newtopia Inc. (NEWU; NEWUF), a leader in tech-enabled habit change solutions, is thrilled to announce its new partnership with a supplemental insurance payvider. This exciting collaboration aims to provide Newtopia's successful habit change platform as a fully-covered benefit for thousands of workers in the...

Continue Reading
A4A Celebrates 250 Years of American Independence through Aviation

Updated Category News Views 94

A4A Launches Campaign for America's 250th Anniversary Airlines for America (A4A) is excited to unveil a memorable campaign, "Red, Flight & Blue—Celebrating America 250," which aims to celebrate the 250th anniversary of the United States. This significant campaign will utilize a variety of platforms, including social media, blog posts, and videos, to highlight the...

Continue Reading
Alexander’s Secures $400M Loan for New York Office Refinancing

Updated Category News Views 238

ALEXANDER’S, INC. concluded a hefty refinancing deal worth $400 million for its office condominium at 731 Lexington Avenue back in 2024. This isn’t just any property; it’s where Bloomberg LP hangs its hat—a landmark in the bustling New York City real estate scene. Traders were glued to this one because it wasn’t just about refinancing but about what it signals...

Continue Reading
IDV Secures Major Contract for Military Logistics Vehicles

Updated Category News Views 239

IDV Secures a Major Tender from the Dutch Armed Forces In a significant development for military logistics, IDV, part of the renowned Iveco Group (EXM: IVG), has successfully secured a contract with the Dutch Ministry of Defence. This contract entails supplying an impressive fleet of 785 military logistics vehicles, which includes three distinct versions: semitrailer...

Continue Reading